Regeneron Pharmaceuticals' Capital Expenditures fell 16.74% to $201.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $849.3 million, marking a year-over-year increase of 5.15%. This contributed to the annual value of $755.9 million for FY2024, which is 5.19% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Capital Expenditures stood at $201.4 million for Q3 2025, which was down 8.04% from $219.0 million recorded in Q2 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Capital Expenditures peaked at $251.4 million during Q4 2023, and registered a low of $113.0 million during Q2 2023.
Its 3-year average for Capital Expenditures is $193.1 million, with a median of $199.6 million in 2024.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Capital Expenditures slumped by 32.22% in 2021, and later surged by 71.25% in 2025.
Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Capital Expenditures stood at $154.9 million in 2021, then fell by 1.74% to $152.2 million in 2022, then soared by 65.18% to $251.4 million in 2023, then fell by 20.60% to $199.6 million in 2024, then dropped by 16.74% to $201.4 million in 2025.
Its last three reported values are $201.4 million in Q3 2025, $219.0 million for Q2 2025, and $229.3 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value